DUBLIN, Feb. 27, 2017 /PRNewswire/ -- Perrigo
Company plc (NYSE; TASE: PRGO), a leading global provider of
Quality Affordable Healthcare Products®, today
announced that Ron Winowiecki,
Senior Vice President, Business Finance, has been appointed acting
Chief Financial Officer, effective immediately, following the
resignation of Judy L. Brown,
Executive Vice President, Business Operations and Chief Financial
Officer, who is leaving Perrigo to take a position with another
company in the pharmaceutical industry, beginning on April 1, 2017. Perrigo is conducting a
thorough search process to identify a permanent Chief Financial
Officer, which includes Mr. Winowiecki as a key candidate.
Perrigo's CEO John T. Hendrickson
commented, "Following the departure of Judy
Brown, I am pleased to announce the appointment of
Ron Winowiecki as acting Chief
Financial Officer. Ron has almost thirty years of accounting and
finance experience, devoting nearly fifteen years to leading global
public company finance organizations in the capacities of Corporate
Controller, Treasurer and Chief Accounting Officer, including eight
years at Perrigo, most recently as Senior Vice President, Business
Finance. I am confident that this will be a seamless transition and
that Ron will provide Perrigo and our financial team with strong
leadership. I look forward to continuing to work alongside
Ron."
Hendrickson continued, "Judy's leadership has been instrumental
in developing a high caliber Finance team at Perrigo and assisted
our efforts to drive growth across our global platform. On behalf
of the Board of Directors and management, I would like to thank
Judy for her contributions to Perrigo over her more than 15-year
tenure with the Company, and wish her all the best in her future
endeavors."
Ron Winowiecki has served as
Perrigo's Senior Vice President, Business Finance since
January 2014. Before serving as
Senior Vice President, Mr. Winowiecki was Perrigo's Vice President,
Treasury and Accounting Shared Services from September 2011 to December
2013 and Corporate Vice President, Treasurer from
October 2008 to August 2011. Prior to joining Perrigo, he served
as CFO for Innotec Company, Vice President Corporate Controller for
SPX Corporation, and the Corporate Controller and Chief Accounting
Officer at Donnelly Corporation. Mr. Winowiecki graduated with a
B.S. in Accounting from Hope College
and received a M.B.A. in Finance from Western
Michigan University.
Perrigo also announced today that Svend
Andersen has been appointed Executive Vice President and
President, Consumer Healthcare International ("CHCI"). The CHCI
segment comprises the Branded Consumer Healthcare business as well
as Perrigo's legacy international businesses. Mr. Andersen will be
responsible for a portfolio mainly consisting of store brand and
branded over-the-counter ("OTC") medicines and products, with
annual sales of more than $1 billion,
and operations across multiple countries. He will report directly
to CEO John Hendrickson and join
Perrigo's Executive Committee.
Commenting on the appointment, Hendrickson said: "The Executive
Committee and I appreciate Sharon
Kochan providing leadership to the branded healthcare team
through a critical period. His efforts to enhance the segment's
leadership team, instill process discipline and drive execution
have prepared the team to thrive under new leadership. As Svend
transitions into his role, Sharon will continue to be a key
executive for our Company and businesses in Australia and Israel."
Hendrickson continued, "Svend brings a proven track record of
commercial execution in Europe
within the consumer, generic and prescription pharmaceuticals
industries, including driving process optimization and ensuring
supply chain and value chain alignment. He will continue to focus
on building and further innovating our OTC portfolios with the
clear goal of enhancing profitability. I look forward to working
closely with Svend and his leadership team to grow this business in
the next phase of our transition."
Most recently, Mr. Andersen served as Executive Vice President –
Europe for LEO-Pharma, where he
successfully initiated restructuring efforts for its 35-country
European business designed to introduce a new OTC strategy and
country-cluster approach, as well as drive process and governance
improvements. Prior to that, he led Hospira, Inc.'s Europe, Middle
East and Africa ("EMEA")
business, where he enhanced its go-to-market strategy and drove
expansion efforts. While at Actavis, Mr. Andersen was responsible
for the Western European division's pharmaceuticals, generics, OTC
and hospital products businesses, and also led Alpharma's EMEA
businesses prior to its acquisition by Actavis.
About Perrigo
Perrigo Company plc, a leading global over-the-counter ("OTC")
consumer goods company, offers patients and customers high quality
products at affordable prices. From its beginning in 1887 as a
packager of home remedies, Perrigo, headquartered in Ireland, has grown to become the world's
largest manufacturer of OTC healthcare products and supplier of
infant formulas for the store brand market. The Company is also a
leading provider of generic extended topical prescription products
in the U.S., and receives royalties from sales of the multiple
sclerosis drug, Tysabri®. Perrigo provides "Quality Affordable
Healthcare Products®" across a wide variety of product categories
and geographies, primarily in North
America, Europe, and
Australia, as well as in other
markets, including Israel,
China, and Latin America. Visit Perrigo online at
(http://www.perrigo.com).
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "estimate," "predict,"
"potential" or the negative of those terms or other comparable
terminology. The Company has based these forward-looking statements
on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including future impairment charges, the ability
to achieve its guidance, the ability to timely execute and achieve
the desired benefits of its announced restructuring plan and
initiatives, future asset sales and the timing, amount and cost of
share repurchases. In addition, there can be no assurance that the
Company will be able to file its 2016 Form 10-K within the fifteen
calendar day extension provided by Rule 12b-25, or that the Company
may not identify one or more material weaknesses in its internal
control over financial reporting, need to restate its financial
statements or conclude that investors should no longer rely upon
previously issued financial statements. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-KT for the six-month period ended December 31, 2015, as well as the Company's
subsequent filings with the SEC, may cause actual results,
performance or achievements to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements in this press release are made only as
of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/perrigo-announces-leadership-changes-300414240.html
SOURCE Perrigo Company plc